Weight-loss dynamics with tirzepatide versus semaglutide
A J Venkatakrishnan, Karthik Murugadoss, Venky Soundararajan, Nancy Brown · 2026
Read Weight-loss dynamics with tirzepatide versus semaglutide by A J Venkatakrishnan, Karthik Murugadoss, Venky Soundararajan, Nancy Brown (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13270487.txt.
Description
A J Venkatakrishnan and co-authors published a journal article in 2026 comparing weight loss on two modern hormone drugs, tirzepatide and semaglutide, in real-world health records. Matched groups of 10,339 patients each were balanced on age, sex, diabetes status, starting weight, and follow-up length. Maximum weight loss over two years was sorted into five response bands.
Tirzepatide patients lost more weight on average, fourteen point seven percent against ten point eight percent. Strong response, at least 15 percent loss in year one, was nearly twice as common, at forty-two point six against twenty-one point six percent. Monthly loss was also faster, at two point five four against two point one eight percent. Tirzepatide showed fewer gut and body-wide side effects in note analysis. Women and White patients were over-represented among strong responders.
Catalog record
| CREATOR | A J Venkatakrishnan, Karthik Murugadoss, Venky Soundararajan, Nancy Brown |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28623 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |